Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market
Daiichi Sankyo said on January 7 that it has launched its HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in the US for the treatment of certain patients with advanced breast cancer. Enhertu, previously known with the code DS-8201, gained…
To read the full story
Related Article
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- Daiichi Sankyo’s DS-8201 Hits Primary Target in PII Gastric Cancer Trial
January 28, 2020
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
BUSINESS
- Sumitomo Notches Record Profit on Strong North America Growth
May 14, 2026
- Takeda’s FY2025 Sales Fall 1.7% on Vyvanse Generic Erosion
May 14, 2026
- Shionogi Nets 4th Straight Year of Record Earnings on Torii Deal, HIV Royalties
May 13, 2026
- Santen’s Eylea Sales Fall 15.9% amid Re-Pricing, Biosimilar Entry
May 13, 2026
- Fuji’s Eylea Biosimilar Logs 776 Million Yen in First 3 Months
May 13, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…